Cellebrite DI Ltd. (CLBT) fair value analysis
Nasdaq · Updated 2026-10-19
CLBT price how computed
Forward Fair Value verdict
UndervaluedCLBT is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $11.03
- Sector
- Technology
- 12-month range
- $10.44–$19.28
- Market cap
- $2.77B
- From 52-week high
- -42.8%
- Shares outstanding
- 251M
- Rank in Technology by discount to fair value
- #26 of 181
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Cellebrite DI Ltd. is a technology company that develops digital intelligence software and services designed to help law enforcement agencies, government organizations, and enterprises extract and analyze data from digital devices including mobile phones, computers, and cloud storage. The company operates globally, serving customers across multiple continents with offices and operations in various countries including the United States, Israel, and other international locations.
CLBT currently ranks #26 of 181 Technology stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $2.77B
- P/E (trailing)
- 25x
- Revenue (TTM)
- $514M
- Net margin
- 11.4%
- EPS (TTM)
- $0.45
- Gross margin
- 80.8%
- Debt / equity
- 0.04
- Revenue growth (3-yr avg)
- 18.6%
- Shares outstanding
- 251M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 41 · neutral
- 50-day average
- $11.71
- 200-day average
- $13.72
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 8 quarters vs consensus
- 5 beat, 1 missed
- Quarter by quarter
- 2026-06 ▼ miss (-44.4%)
2026-03 ▲ beat (+20.0%)
2025-12 ▬ met (0.0%)
2025-09 ▲ beat (+7.7%)
2025-06 ▲ beat (+9.1%)
2025-03 ▲ beat (+11.1%)
2024-12 ▬ met (0.0%)
2024-09 ▲ beat (+55.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 0 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $15.4
- Target vs last price
- +39.6%
What our data shows for CLBT
- Our model validated 17 trailing price-to-earnings windows for CLBT, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $10.44–$19.28.
- The 14-day relative strength index sits at a neutral 41.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CLBT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CLBT news
TickrTrends' derived news-sentiment signal for CLBT is currently leaning positive, computed from recent coverage.
- Cellebrite เตรียมรายงานผลประกอบการไตรมาส 3 ปี 2569 ในวันที่ 12 พฤศจิกายน 2569 (prnewswire.com, 2026-10-20)
TickrTrends take: Cellebrite is scheduled to report third quarter 2025 results on November 12, 2025, which will provide investors with updated financial metrics to assess against its current undervalued standing according to TickrTrends analysis. For valuation-focused readers, the earnings report will be an opportunity to examine whether the company's financial performance supports or challenges the undervalued verdict in the Technology sector. Key metrics from the quarter, including revenue trends and profitability measures, will be important to monitor for any changes to the valuation assessment. - Cellebrite to Report Third-Quarter 2026 Financial Results on November 12, 2026 (prnewswire.com, 2026-10-20)
TickrTrends take: Cellebrite's scheduled third-quarter 2026 earnings announcement on November 12, 2026 will provide critical data points for assessing whether the company's current undervalued status according to TickrTrends remains justified or if operational performance warrants valuation adjustment. Investors monitoring the technology sector should focus on revenue trends, margin dynamics, and forward guidance as material factors that could confirm or challenge the existing undervaluation thesis. The earnings report will offer concrete financial metrics against which the market's current pricing of CLBT can be evaluated. - Pertento Partners LLP Adds Cellebrite DI Ltd (CLBT) -- Shares Look 35% Undervalued on GF Value (gurufocus.com, 2026-10-15)
TickrTrends take: Cellebrite DI Ltd (CLBT) is currently assessed as undervalued by TickrTrends within the Technology sector, which aligns with an external valuation analysis suggesting the stock trades at a 35% discount to intrinsic value estimates. For investors focused on valuation metrics, the consistency between multiple analytical perspectives on undervaluation presents a point worth monitoring as market conditions and company fundamentals evolve. Watchers of this stock should track whether the gap between current price and estimated fair value narrows as investor sentiment shifts or as new financial results emerge.
More CLBT news
- Is Cellebrite DI Ltd (CLBT) a Bargain After 5.1% Drop? GF Value Says Undervalued (gurufocus.com, 2026-09-25)
- Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals (manilatimes.net, 2026-09-17)
- CLBT Maintained by DA Davidson -- Price Target Stays at $15 (gurufocus.com, 2026-09-15)
What people are saying
Follow the CLBT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — CLBT's sector discount rank improved to 40 this week, up from 50 the previous week, indicating the stock is trading at a smaller discount relative to other technology sector companies. The stock maintains an undervalued valuation verdict according to TickrTrends' derived indicators.
- 2026-09-21 — TickrTrends' derived indicators for CLBT show a shift in relative strength this week, with the RSI zone moving from oversold to neutral territory. The stock maintains an undervalued verdict based on current valuation metrics. This improvement in the RSI indicator suggests the technology sector stock has moved away from extreme selling pressure.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CLBT stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), CLBT is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is CLBT's TickrTrends verdict?
CLBT's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does CLBT compare to other Technology stocks?
CLBT ranks #26 of 181 Technology stocks in TickrTrends' coverage by discount to fair value.
Is CLBT overbought or oversold?
CLBT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CLBT report earnings next?
CLBT's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does CLBT usually beat earnings estimates?
Over its last 8 reported quarters CLBT beat the consensus estimate 5 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CLBT?
Of 8 analysts covering CLBT, 8 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $15.4 (+39.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Technology
Head-to-head comparisons
CLBT vs ACN · CLBT vs ADSK · CLBT vs APPF · CLBT vs CGNX · CLBT vs CHYM